Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Cell Culture-Derived vs Egg-Derived Influenza Vaccine in Children and Adolescents
NCT00645411Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2007
- Primary completion
- Feb 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
A Phase 3 trial of Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated) in influenza, sponsored by Novartis. Started Oct 2007; status: completed.
02
Drugs
Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00645411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00645411.